This retrospective case control study investigated the therametric value of the circulating c-erbB-2 gene product (Her-2, NEU) as (1) an eligibility criterion for high doses of chemotherapy and (2) response to standard adjuvant chemotherapy in node-positive breast cancer patients.
Preoperative c-erbB-2 levels were measured in 211 locally advanced (>3 nodes positive), pre-and perimenopausal breast cancer patients to determine if circulating levels of the gene product can assist in the determination of appropriate therapeutic options. 152 of 211 breast cancer patients received post-operatively a combination chemotherapy including the anthracycline analog mitoxantrone. while 59 patients were treated with conventional CMF therapy.
Using 120 fmol/ml as a cut-off level, elevated c-erbB-2 values were found in 26 (12.3%) patients with locally advanced breast cancer.
In univariate analysis significant survival differences were detected when c-erbB-2'positive'patients were compared with c-erbB-2'negative'patients.
However, no significant survival differences were detected, when c-erbB-2'positive'patients were compared according to regimen of adjuvant treatment.
In multivariate analysis c-erbB-2 was an independent prognostic factor for predicting disease-free survival, but not for overall survival.
High levels of c-erbB-2 were associated with low estrogen and progesterone receptor concentrations of the tumor cytosol. (...)
Mots-clés Pascal : Mitoxantrone, Cyclophosphamide, Méthotrexate, Fluorouracil, Association médicamenteuse, Tumeur maligne, Glande mammaire, Etude cas témoin, Dose forte, Chimiothérapie, Traitement adjuvant, Traitement, Gène onc cellulaire, Pronostic, Homme, Epidémiologie, Anticancéreux, Rétrospective, Moutarde à l'azote, Oxazaphosphinane dérivé, Antifolate, Antimétabolite, Fluoropyrimidine dérivé, Glande mammaire pathologie, Sang, Taux concentration, Gène neu, Gène erbB
Mots-clés Pascal anglais : Mitoxantrone, Cyclophosphamide, Methotrexate, Fluorouracil, Drug combination, Malignant tumor, Mammary gland, Case control study, High dose, Chemotherapy, Adjuvant treatment, Treatment, C-Onc gene, Prognosis, Human, Epidemiology, Antineoplastic agent, Retrospective, Nitrogen mustard, Oxazaphosphinane derivatives, Antifolate, Antimetabolic, Fluoropyrimidine derivatives, Mammary gland diseases, Blood, Concentration factor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0226830
Code Inist : 002B02R02. Création : 11/06/1997.